Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 5/20 | 0.33 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740513 | 0.95 | FPR2 (0.35) | FPR2GSTO1OPRD1OPRK1 | |
| SCHEMBL1742277 | 0.87 | ESR1 (0.33) | — | |
| SCHEMBL2498914 | 0.82 | FPR2 (0.44) | FPR2OPRD1OPRK1 | |
| SCHEMBL10261192 | 0.80 | POLB (0.41) | FPR2 | |
| SCHEMBL15193599 | 0.80 | FPR2 (0.30) | FPR2 | |
| SCHEMBL11930752 | 0.75 | FPR2 (0.34) | FPR2OPRD1OPRK1 | |
| SCHEMBL4235144 | 0.74 | SMN1; SMN2 (0.37) | FPR2OPRD1OPRK1 | |
| SCHEMBL11937134 | 0.74 | FPR2 (0.34) | FPR2OPRD1OPRK1 | |
| SCHEMBL15899642 | 0.74 | SMN1; SMN2 (0.32) | FPR2 | |
| SCHEMBL11930732 | 0.74 | ALDH1A1 (0.38) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505192-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | Molecular Insight Pharmaceuticals, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2739316-B1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARM INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9433594-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2389361-B1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARM INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9422251-B2 | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-9388144-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| EP-2706057-B1 | Bis(imidazolyl)compounds and radionuclide complexes | MOLECULAR INSIGHT PHARM INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160009664-A1 | METAL COMPLEXES OF POLY(CARBOXYL)AMINE-CONTAINING LIGANDS HAVING AN AFFINITY FOR CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2016-01-14 | — | — | US | disclosed |
| US-9120837-B2 | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-09-01 | — | — | US | disclosed |
| US-8211402-B2 | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2389361-A2 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| EP-2373621-A2 | TECHNETIUM-AND RHENIUM-BIS(HETEROARYL)COMPLEXES AND METHODS OF USE THEREOF | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2373622-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2010065902-A2 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065906-A2 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065899-A2 | TECHNETIUM-AND RHENIUM-BIS(HETEROARYL)COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | PSMA1, PSMA5, PSMA3 | FPR2 4575/4885GSTO1 3183/4885OPRD1 3767/4885 |
| US-20160009664-A1 | METAL COMPLEXES OF POLY(CARBOXYL)AMINE-CONTAINING LIGANDS HAVING AN AFFINITY FOR CARBONIC ANHYDRASE IX | CA9, CA4, CA7 | FPR2 4289/4885GSTO1 4342/4885OPRD1 1532/4885 |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | FPR2 1849/4885GSTO1 1306/4885OPRD1 1744/4885 |
| US-20100178247-A1 | CA-IX SPECIFIC RADIOPHARMACEUTICALS FOR THE TREATMENT AND IMAGING OF CANCER | CA9, CA13, CA14 | FPR2 3982/4885GSTO1 4217/4885OPRD1 4264/4885 |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | SSTR5, SSTR3, SSTR4 | FPR2 1076/4885GSTO1 4314/4885OPRD1 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.